Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Activating mutations in epidermal growth factor receptor (EGF-R) are key predictors of gefitinib efficacy.
• The concept of oncogene addiction is central to understanding targeted cancer therapy.
• Common cancers often possess multiple oncogenic alterations, complicating selective drug responses.

Purpose of the Study:

• To analyze the impact of EGF-R mutations on targeted cancer therapy strategies.
• To compare EGF-R and Bcr-Abl as drug targets and explore oncogene addiction.
• To discuss the role of molecular diagnostics in identifying cancers responsive to targeted agents.

Main Methods:

• Comparative analysis of EGF-R and Bcr-Abl as oncologic targets.
• Discussion of oncogene addiction in cancer treatment.
• Exploration of combination therapy strategies for common cancers.

Main Results:

• Mutant EGF-R serves as a validated target for selective cancer therapy.
• Oncogene addiction necessitates molecular diagnostics for patient stratification.
• Common cancers with multiple oncogenic alterations are unlikely to respond to selective drugs alone.

Conclusions:

• Targeted therapies, like gefitinib for mutant EGF-R, are effective for specific cancer subtypes.
• Combination strategies involving non-specific cytotoxic agents and selective drugs are crucial for treating common cancers.
• Molecular diagnostics are essential for advancing personalized and effective cancer treatment approaches.